Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

BACKGROUND: Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced non‐small cell lung carcinoma (NSCLC) and positive programmed cell death ligand 1 (PD‐L1). However, no direct comparison da...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yixin, Zhang, Yaqiong, Guo, Guifang, Cai, Xiuyu, Yu, Hui, Cai, Yanyu, Zhang, Bei, Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240850/
https://www.ncbi.nlm.nih.gov/pubmed/32508007
http://dx.doi.org/10.1002/ctm2.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240850/
https://www.ncbi.nlm.nih.gov/pubmed/32508007
http://dx.doi.org/10.1002/ctm2.14

Ejemplares similares